FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3161796718> ?p ?o ?g. }

• W3161796718 endingPage "566" @default.
• W3161796718 startingPage "555" @default.
• W3161796718 abstract "Pathogenesis of atopic dermatitis (AD) involves the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. A cream formulation of ruxolitinib, a potent selective JAK1/JAK2 inhibitor, was developed for topical delivery.Pharmacokinetic data were obtained from three double-blind, vehicle-controlled studies in patients with AD: a phase II study with ruxolitinib cream 0.15%, 0.5%, or 1.5% once daily or 1.5% twice daily (BID), and two phase III studies with 0.75% or 1.5% BID. Effects of baseline characteristics on pharmacokinetics were examined. Correlations were attempted between plasma concentrations and change in hematological parameters over time.Ruxolitinib plasma concentrations at steady-state (Css) increased with cream strength in a less-than-dose-proportional manner. In the phase III studies, overall mean (standard deviation [SD]) Css after ruxolitinib cream 0.75% and 1.5% BID (23.8 [35.0] and 35.7 [55.0] nM) were a fraction of the half-maximal inhibitory concentration for thrombopoietin-stimulated phosphorylated STAT3 inhibition (281 nM), a JAK/STAT signaling marker. Three covariates were identified for Css: dose, percent body surface area (%BSA) treated, and baseline Investigator's Global Assessment score. Mean (SD) bioavailability of ruxolitinib cream 1.5% BID was 6.22% (7.66%). There were no correlations between Css and any hematological changes except for a transient increase in platelets at week 2.Plasma ruxolitinib concentrations after treatment with topical ruxolitinib cream in patients with up to 20% BSA affected by AD are not expected to lead to systemic plasma concentrations that may be associated with adverse effects commonly associated with oral JAK inhibitors. CLINICALTRIALS.GOV: NCT03011892; NCT03745638; NCT03745651." @default.
• W3161796718 created "2021-05-24" @default.
• W3161796718 creator A5011862588 @default.
• W3161796718 creator A5012830519 @default.
• W3161796718 creator A5037490285 @default.
• W3161796718 creator A5039412958 @default.
• W3161796718 creator A5041230347 @default.
• W3161796718 creator A5044007154 @default.
• W3161796718 creator A5085748147 @default.
• W3161796718 creator A5090351184 @default.
• W3161796718 date "2021-05-12" @default.
• W3161796718 modified "2023-10-11" @default.
• W3161796718 title "Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies" @default.
• W3161796718 cites W1836238490 @default.
• W3161796718 cites W1951033806 @default.
• W3161796718 cites W1971402668 @default.
• W3161796718 cites W1982385791 @default.
• W3161796718 cites W1984525156 @default.
• W3161796718 cites W1990636742 @default.
• W3161796718 cites W2018254868 @default.
• W3161796718 cites W2045163297 @default.
• W3161796718 cites W2051521434 @default.
• W3161796718 cites W2060621834 @default.
• W3161796718 cites W2077990797 @default.
• W3161796718 cites W2079645940 @default.
• W3161796718 cites W2085716005 @default.
• W3161796718 cites W2104303439 @default.
• W3161796718 cites W2104822980 @default.
• W3161796718 cites W2107694331 @default.
• W3161796718 cites W2116889630 @default.
• W3161796718 cites W2117983771 @default.
• W3161796718 cites W2120110016 @default.
• W3161796718 cites W2121743767 @default.
• W3161796718 cites W2123633897 @default.
• W3161796718 cites W2138423109 @default.
• W3161796718 cites W2142327072 @default.
• W3161796718 cites W2142501647 @default.
• W3161796718 cites W2200308911 @default.
• W3161796718 cites W2465799764 @default.
• W3161796718 cites W2598690588 @default.
• W3161796718 cites W2604389567 @default.
• W3161796718 cites W2606268778 @default.
• W3161796718 cites W2620112591 @default.
• W3161796718 cites W2623738179 @default.
• W3161796718 cites W2758867833 @default.
• W3161796718 cites W2799381018 @default.
• W3161796718 cites W2801208468 @default.
• W3161796718 cites W2820763047 @default.
• W3161796718 cites W2883568898 @default.
• W3161796718 cites W2890212733 @default.
• W3161796718 cites W2899071879 @default.
• W3161796718 cites W2899159625 @default.
• W3161796718 cites W2901898022 @default.
• W3161796718 cites W2905252141 @default.
• W3161796718 cites W2913292104 @default.
• W3161796718 cites W2979754363 @default.
• W3161796718 cites W2981004305 @default.
• W3161796718 cites W2990076552 @default.
• W3161796718 cites W3005910897 @default.
• W3161796718 cites W3013746041 @default.
• W3161796718 cites W3033283522 @default.
• W3161796718 cites W3159897478 @default.
• W3161796718 cites W3214321974 @default.
• W3161796718 cites W4211044813 @default.
• W3161796718 cites W4248752041 @default.
• W3161796718 doi "https://doi.org/10.1007/s40257-021-00610-x" @default.
• W3161796718 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8200345" @default.
• W3161796718 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33982267" @default.
• W3161796718 hasPublicationYear "2021" @default.
• W3161796718 type Work @default.
• W3161796718 sameAs 3161796718 @default.
• W3161796718 citedByCount "32" @default.
• W3161796718 countsByYear W31617967182021 @default.
• W3161796718 countsByYear W31617967182022 @default.
• W3161796718 countsByYear W31617967182023 @default.
• W3161796718 crossrefType "journal-article" @default.
• W3161796718 hasAuthorship W3161796718A5011862588 @default.
• W3161796718 hasAuthorship W3161796718A5012830519 @default.
• W3161796718 hasAuthorship W3161796718A5037490285 @default.
• W3161796718 hasAuthorship W3161796718A5039412958 @default.
• W3161796718 hasAuthorship W3161796718A5041230347 @default.
• W3161796718 hasAuthorship W3161796718A5044007154 @default.
• W3161796718 hasAuthorship W3161796718A5085748147 @default.
• W3161796718 hasAuthorship W3161796718A5090351184 @default.
• W3161796718 hasBestOaLocation W31617967181 @default.
• W3161796718 hasConcept C112392421 @default.
• W3161796718 hasConcept C112705442 @default.
• W3161796718 hasConcept C126322002 @default.
• W3161796718 hasConcept C170493617 @default.
• W3161796718 hasConcept C181389837 @default.
• W3161796718 hasConcept C197934379 @default.
• W3161796718 hasConcept C203014093 @default.
• W3161796718 hasConcept C22979827 @default.
• W3161796718 hasConcept C2776112149 @default.
• W3161796718 hasConcept C2776233030 @default.
• W3161796718 hasConcept C2777575956 @default.
• W3161796718 hasConcept C2778329239 @default.
• W3161796718 hasConcept C2778886723 @default.

• next